Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?
- PMID: 31187471
- DOI: 10.1007/s40262-019-00784-y
Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?
Comment in
-
Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?".Clin Pharmacokinet. 2019 Jul;58(7):979-980. doi: 10.1007/s40262-019-00787-9. Clin Pharmacokinet. 2019. PMID: 31187472 No abstract available.
Comment on
-
Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3. Clin Pharmacokinet. 2019. PMID: 30949873 Free PMC article.
References
-
- Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-007747-3 . - DOI - PubMed - PMC
-
- Lindenblatt, et al. Solid pharmaceutical preparation containing levothyroxine. United States Patent Application Publication. Merck patent GMBH. US 2015/0231101 A1. 2015.
-
- ANSM. Direction des contrôles. 12/09/2017. Note de synthèse 17-A-033.
-
- Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministrated with various calcium formulations. Thyroid. 2011;21:483–6. - DOI
-
- Poole RA, Kasper PT, Jiskoot W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations. J Pharm Sci. 2011;100:3018–22. - DOI